[go: up one dir, main page]

WO2020229412A1 - Traitement du syndrome prémenstruel et/ou d'une gêne menstruelle par une composition comprenant de la vicénine -2 - Google Patents

Traitement du syndrome prémenstruel et/ou d'une gêne menstruelle par une composition comprenant de la vicénine -2 Download PDF

Info

Publication number
WO2020229412A1
WO2020229412A1 PCT/EP2020/063054 EP2020063054W WO2020229412A1 WO 2020229412 A1 WO2020229412 A1 WO 2020229412A1 EP 2020063054 W EP2020063054 W EP 2020063054W WO 2020229412 A1 WO2020229412 A1 WO 2020229412A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
symptom
apigenin
vicenin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2020/063054
Other languages
English (en)
Inventor
Emmanuel FRIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Besins Healthcare Ireland Ltd
Original Assignee
Besins Healthcare Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Ireland Ltd filed Critical Besins Healthcare Ireland Ltd
Publication of WO2020229412A1 publication Critical patent/WO2020229412A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Definitions

  • the present invention relates to compositions that are useful in the treatment of female subjects suffering from premenstrual syndrome and/or menstrual discomfort. Furthermore, the invention relates to the prevention, curing and/or alleviation of at least one symptom associated with premenstrual syndrome and/or menstrual discomfort using the compositions of the invention.
  • PMS Premenstrual syndrome
  • the central element seems to be a change in capillary permeability accompanied by the formation of an interstitial tissular oedema mainly in the breasts (mastalgia), the brain (neuropsychological manifestations), and the abdominopelvic cavity (abdominopelvic disorders).
  • PMDD Premenstrual Dysphoric Disorder
  • premenstrual syndrome can be divided into three main categories, notably breast symptoms, psychological/mental symptoms and abdominopelvic symptoms.
  • Breast symptoms can be a simple mastodynia but with really painful and tense breasts.
  • Psychological/mental symptoms include irritability, anxiety and depression.
  • Abdominopelvic symptoms can consist of more or less pronounced bloating, potentially associated with transit issues and/or weight gain. Other symptoms may include food craving.
  • the defining criteria for diagnosis of premenstrual syndrome include at least one moderate to severe mood symptom and one physical symptom ( Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology. 2003 Aug;28 Suppl 3:39-53. Review).
  • menstrual discomfort involves a variety of physical and mental symptoms, which symptoms typically peak during menses of a woman's cycle. Said symptoms include for example abdominal pain, back pain, cramps, breast tenderness, mood changes, headaches, nausea and/or dizziness. The severity of these symptoms ranges from mild to incapacitating. Increased menstrual discomfort is the most common medical reason reported for copper IUD removal.
  • compositions in particular in the form of dietary supplements, that can be used effectively in the treatment of female subjects suffering from and/or at risk of suffering from PMS and/or menstrual discomfort. It is a further object of the invention to provide treatments based on the administration of said compositions.
  • vicenin-2 and composition comprising vicenin-2 can be used effectively in the treatment of female subjects suffering from and/or at risk of suffering from premenstrual syndrome and/or menstrual discomfort.
  • the treatment of female subjects with a dietary supplement comprising vicenin-2 results in the prevention, treatment or alleviation of one or more symptoms associated with premenstrual syndrome and/or menstrual discomfort, as can be assessed using prospective diaries (COPE, Calendar of Premenstrual Events) or similar self-assessment protocols.
  • the invention thus resides in the use of vicenin-2 as an active ingredient for use in a treatment of premenstrual syndrome and/or menstrual discomfort.
  • the invention provides compositions, especially pharmaceutical and/or nutraceutical formulations, comprising vicenin-2 as a pharmacologically and/or physiologically active ingredient.
  • the present invention also provides methods of treatment of subjects in need thereof using vicenin-2 and compositions comprising vicenin-2.
  • the invention accordingly also provides vicenin-2 and compositions comprising vicenin-2 for use in the treatment of subjects in need thereof.
  • vicenin-2 has an anti-cancer, anti-inflammatory, antinociceptive, antispasmodic or prokinetic effect.
  • vicenin-2 has an anti-cancer, anti-inflammatory, antinociceptive, antispasmodic or prokinetic effect.
  • its use in the treatment of premenstrual syndrome and/or of menstrual discomfort is new.
  • compositions comprising, besides vicenin-2, one or more further pharmacologically and/or physiologically active ingredients.
  • the present invention thus provides compositions, especially pharmaceutical and/or nutraceutical formulations, comprising vicenin-2 in association with one or more further ingredients.
  • the present invention also provides methods of treatment of subjects in need thereof using compositions comprising vicenin-2 in association with one or more further ingredients.
  • the invention accordingly also provides compositions comprising vicenin-2 in association with one or more further ingredients for use in the treatment of subjects in need thereof.
  • a first aspect of the invention provides compositions comprising vicenin-2, such as pharmaceutical formulations and/or food supplement products comprising vicenin-2 in association with one or more further ingredients, typically one or more further active ingredients and/or one or more excipients.
  • Vicenin-2 is a naturally occurring apigenin glycoside. It has CAS Registry Number 23666-13-9.
  • the systematic (lUPAC) name is 5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8- bis[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6 (hydroxymethyl)oxan-2-yl]chromen-4-one).
  • Common synonyms include apigenin-6,8-di-C-b-D-glycoside; apigenin-6,8-di-C-b-D- glucopyranoside; and 5,7,4'-trihydroxyflavone-6,8-di-C-glucoside.
  • Vicenin-2 has the following molecular structure:
  • Vicenin-2 occurs naturally in various plants, such as plants in the genera artemisia, perilla, urtica, passiflora, camelia, cayaponia, colocasia, desmodium, hordeum, origanum, ocimum, jatropha, parkinsonia, peperomia, piheranthos, centaurea, indigo, bomba, lychnophera, asplenium, chinotto, citrus, viola, trigonella, lamiacea, labiatae, lavandula, nipponanthemum, abrus, santalum, oryza, scleropyrum, tulsi, indigofera, bombax, glinus, lychnophora, urticaceae, rosales, malpighiales, thymus, prunus, camellia, olea, brassica, apium, petroselinum, matricaria, chamaemelum, and chry
  • vicenin-2 may be found in vitex agnus-castus, petroselinum crispum, apium graveolens, citrus paradisi, citrus maxima, perilla frutescens, Matricaria chamomilla, chrysanthemum morifolium and chamaemelum nobile.
  • Plants of particular interest as a vicenin-2 source are plants in the perilla genus, such as perilla frutescens.
  • compositions of the invention may be obtained by extraction or isolation from a natural source or by chemical synthesis.
  • the compositions of the invention comprise vicenin-2 in the form of an extract.
  • the compositions of the invention comprise vicenin-2 in the form of an extract from a plant material derived from a plant species in a genus selected from the group consisting of artemisia, perilla, urtica, passiflora, camelia, cayaponia, colocasia, desmodium, hordeum, origanum, ocimum, jatropha, parkinsonia, peperomia, piheranthos, centaurea, indigo, bomba, lychnophera, asplenium, chinotto, citrus, viola, trigonella, lamiacea, labiatae, lavandula, nipponanthemum, abrus, santalum, oryza, scleropyrum, tulsi, indigofera, bomba
  • compositions of the invention comprise vicenin-2 in the form of an extract from plant material derived from vitex agnus- castus, petroselinum crispum, apium graveolens, citrus paradisi, citrus maxima, perilla frutescens, Matricaria chamomilla, chrysanthemum morifolium or chamaemelum nobile.
  • the plant material preferably comprises or consists of seed.
  • the composition comprises vicenin-2 in the form of a Perilla extract, preferably a Perilla seed extract, more preferably a Perilla frutescens (L.) Britton extract, most preferably a Perilla frutescens (L.) Britton seed extract.
  • said Perilla extract is made from sun-dried seeds which were harvested in autumn.
  • Suitable extracts can be produced with polar solvents, such as with water, methanol, ethanol and mixtures thereof.
  • the extract is produced with a solvent having a relative polarity of more than 0.5, such as more than 0.6 or more than 0.7.
  • Relative polarity values are known to the skilled person, preferably the relative polarity is determined as a normalized value from measurements of solvents shifts of adsorption spectra, wherein water has a relative polarity value of 1 , as explained in Christian Reichardt, Solvents and Solvent Effects in Organic Chemistry, Wiley-VCH Publishers, 3rd ed., 2003.
  • Preferred extracts can be produced with water, with alcohols, in particular methanol, ethanol, propanol or mixtures thereof, or with mixture of water and alcohol, preferably mixtures with a level of alcohol within the range of 10-95 %(v/v), 30-90 %(v/v) or 60-80 %(v/v) as the extraction solvent.
  • the extract is produced with water, methanol, ethanol, water-ethanol or water-methanol mixtures.
  • the extract is produced with water, ethanol, or water-ethanol mixtures.
  • Highly preferred extracts can be produced with water as the sole/main extraction solvent, since some volatile, allergenic compounds like perillaldehyde, methyleugenol and myristicin, which may occur in the plant material containing vicenin-2 can be eliminated by (hot) water extraction.
  • the composition comprises vicenin-2 in the form of an aqueous extract, preferably an extract obtained using water as the sole extraction solvent (referred to herein as a‘100% water extract’), of a vicenin-2 comprising plant material as described above.
  • a composition as defined herein comprising an aqueous extract, preferably a 100% water extract, of a vicenin-2 comprising plant material.
  • the composition comprises vicenin-2 in the form of an aqueous extract, preferably a 100% water extract, from Perilla, preferably fromPerilla seed, more preferably from Perilla frutescens (L.) Britton, most preferably from Perilla frutescens (L.) Britton seed, wherein the extraction was performed at a temperature of more than 60°C, preferably more than 80°C, most preferably more than 95°C.
  • the composition comprises vicenin-2 in the form of an extract, preferably an aqueous extract, more preferably a 100% water extract, wherein the extract comprises less than 0.1 wt.% myristicine, based on the total weight of the plant derived components, preferably less than 0.01 wt.% myristicine.
  • Aqueous, preferably 100% water vicenin-2 containing plant extracts may typically comprise one, two, three, four or five additional active ingredients selected from the group consisting of perilloside A, perilloside E, trihydroxyflavones, scutellarin, caffeic acid, prunasin, luteolin, chrysoeriol, apigenin, shisonin, scutellarein, coumaroyl tartaric acid, linolenic acid, linoleic acid, oleic acid, stearic acid, rosmarinic acid and palmitic acid.
  • the composition comprises a vicenin- 2 containing plant extract having a vicenin-2 level of at least 0.1 wt.%, based on the total weight of the plant derived components or based on total dry solids weight, e.g. at least 0.5 wt.%, at least 1 wt.%, at least 2 wt.%, at least 3 wt.%, at least 4 wt.% or at least 5 wt.%.
  • the composition comprises a vicenin- 2 containing plant extract obtainable by aqueous extraction, preferably extraction with water as the sole extraction solvent, performed in such a way that an extract is produced that, excluding any extraction solvent, is from 1/6 - 1/4 of the (dry) weight of the plant material before extraction.
  • the composition comprises a vicenin- 2 containing plant extract obtainable by a method comprising the steps of:
  • step a) providing Perilla plant material, preferably Perilla frutescens (L.) Britton seed; b) macerating or grinding the plant material provided in step a);
  • compositions as defined herein are provided, further comprising rosmarinic acid.
  • Rosmarinic acid is a naturally occurring compound belonging to the class of phenolic acids. It has CAS Registry Number 20283-92-5.
  • the systematic (lUPAC) name is 3,4-dihydroxy-a-[[3-(3,4-dihydroxyphenyl)- 1-oxo-2-propenyl7-oxy7-phenyl-propionic acid.
  • Rosmarinic acid has the following molecular structure: Rosmarinic acid
  • Rosmarinic acid occurs naturally in various plants, such as plants in the families Lamiaceae, Boraginaceae, and Marantaceae. It is, for example, found in plants of the genera ocimum, melissa, rosmarinus, origanum, salvia, thymus, prunella, stachys, heliotropium, maranta, thalia, perilla, mentha, celastrus etc.
  • rosmarinic acid may be found in ocimum basilicum, ocimum tenuiflorium, melissa officinalis, rosmarinus officinalis, origanum majorana, salvia officinalis, thymus vulgaris, mentha x piperita, prunella vulgaris, stachys sylvatica, heliotropium foertherianum, maranta leuconeura, maranta depressa, thalia geniculata, anthoceros agrestis, perilla fruescens, salvia officialis, mentha arvense, celastrus hindsii etc.
  • Rosmarinic acid may be obtained by extraction or isolation from a natural source or by chemical synthesis.
  • the compositions of the invention comprise rosmarinic acid in the form of an extract.
  • the compositions of the invention comprise rosmarinic acid in the form of an extract from a plant material derived from a plant species in a genus selected from the group consisting of ocimum, melissa, rosmarinus, origanum, salvia, thymus, prunella, stachys, heliotropium, maranta, thalia, perilla, mentha and celastrus.
  • compositions of the invention comprise rosmarinic acid in the form of an extract from a plant material derived from ocimum basilicum, ocimum tenuiflorium, melissa officinalis, rosmarinus officinalis, origanum majorana, salvia officinalis, thymus vulgaris, mentha x piperita, prunella vulgaris, stachys sylvatica, heliotropium foertherianum, maranta leuconeura, maranta depressa, thalia geniculata, anthoceros agrestis, perilla fruescens, salvia officialis, mentha arvense and celastrus hindsii.
  • the plant material preferably comprises or consists of whole plants, preferably leaves, flowers and/or stem, more preferably leaves and/or flowers, most preferably leaves.
  • the composition comprises rosmarinic acid in the form of a Perilla extract, preferably a Perilla seed extract, more preferably a Perilla frutescens (L.) Britton extract, most preferably a Perilla frutescens (L.) Britton seed extract.
  • Suitable extracts can be produced with polar solvents, such as with water, methanol, ethanol and mixtures thereof.
  • the extract is produced with a solvent having a relative polarity of more than 0.5, such as more than 0.6 or more than 0.7.
  • Preferred extracts can be produced with water, methanol, ethanol, propanol or mixtures thereof, preferably with a level of alcohol within the range of 10-95 %(v/v), 30-90 %(v/v) or 60-80 %(v/v) as the extraction solvent.
  • the extract is produced with water, methanol, ethanol or water-ethanol or water-methanol mixtures.
  • the extract is produced with water, ethanol, or water-ethanol mixtures. Most preferably, the extract is produced with a water-ethanol mixture.
  • the extract is produced with a water-ethanol mixture with a level of ethanol within the range of 20-90 %(v/v), preferably within the range of 40-90 %(v/v), preferably within the range of 60-80 %(v/v), preferably within the range of 65-75 %(v/v).
  • Highly preferred extracts can be produced with water as the sole/main extraction solvent, referred to as a 100 % water extract, since some volatile, allergenic compounds like perillaldehyde, methyleugenol and myristicin, which may occur in the plant material can be eliminated by (hot) water extraction.
  • the composition comprises rosmarinic acid in the form of an aqueous extract, preferably a 100% water extract of a rosmarinic acid comprising plant material as described above.
  • a composition as defined herein comprising an aqueous extract, preferably a 100% water extract, of a rosmarinic acid comprising plant material.
  • the composition comprises rosmarinic acid in the form of an aqueous extract, preferably a 100% water extract, from Perilla, preferably from Perilla seed, more preferably from Perilla frutescens (L.) Britton, most preferably from Perilla frutescens (L.) Britton seed, wherein the extraction was performed at a temperature of more than 60°C, preferably more than 80°C, most preferably more than 95°C.
  • the composition comprises rosmarinic acid in the form of an extract, preferably an aqueous extract, more preferably a 100% water extract, wherein the extract comprises less than 0.1 wt.% myristicine, based on the total weight of plant derived component or based on total dry solids weight, preferably less than 0.01 wt.% myristicine.
  • Rosmarinic acid containing plant extracts may typically comprise one, two, three, four or five additional active ingredients selected from the group consisting of vicenin-2, perilloside A, perilloside E, trihydroxyflavones, scutellarin, caffeic acid, prunasin, luteolin, chrysoeriol, apigenin, shisonin, scutellarein, coumaroyl tartaric acid, linolenic acid, linoleic acid, oleic acid, stearic acid, and palmitic acid.
  • additional active ingredients selected from the group consisting of vicenin-2, perilloside A, perilloside E, trihydroxyflavones, scutellarin, caffeic acid, prunasin, luteolin, chrysoeriol, apigenin, shisonin, scutellarein, coumaroyl tartaric acid, linolenic acid, linole
  • the composition comprises a rosmarinic acid containing plant extract, having a rosmarinic acid level of at least 0.01 wt.%, based on the weight of the rosmarinic acid containing plant extract essentially free of extraction solvent, e.g. at least 0.05 wt.%, at least 0.1 wt.%, at least 0.5 wt.%, or at least 2 wt.%.
  • a suitable way to determine the rosmarinic acid content is by high performance liquid chromatography (HPLC) using a Develosil HG-5 column (Nomura Chemical Co., Ltd., Aichi, Japan) with solvents A (0.1 % v/v trifluoroacetic acid [TFA] in distilled water) and B (0.1 % v/v TFA in acetonitrile) under the following conditions: 10%-50% linear gradient of A in B; flow rate of 0.8 ml/min; and detection at 280 nm.
  • HPLC high performance liquid chromatography
  • the composition comprises a rosmarinic acid containing plant extract obtainable by aqueous extraction, preferably by extraction with water as the sole extraction solvent, referred to herein as‘100% water extraction’, performed in such a way that an extract is produced that, excluding any extraction solvent, is from 1/6 - 1/4 of the (dry) weight of the plant material before extraction.
  • the composition comprises a rosmarinic acid containing plant extract obtainable by a method comprising the steps of: a) providing Perilla plant material, preferably Perilla frutescens (L.) Britton seed; b) preferably macerating or grinding the plant material provided in step a);
  • Rosmarinic acid containing extracts suitable for use in the context of the present invention, and the production thereof, have been described in the prior art, e.g. in
  • an extract such as the Perilla extracts as defined herein, is incorporated in the composition as a source of both vicenin-2 as well as rosmarinic acid.
  • compositions as defined herein are provided, further comprising one or more clerodane diterpenoids, preferably one or more clerodadienols.
  • Clerodadienols are naturally occurring diterpenes which have a cleroda-x, 14-dien- 13-ol skeleton.
  • the clerodadienol skeleton has the following molecular structure:
  • Clerodadienols occur naturally in plants and herbs, such as Vitex agnus-castus, also known as the chastetree.
  • Clerodadienols may be obtained by extraction or isolation from a natural source or by chemical synthesis.
  • the compositions of the invention comprise one or more clerodadienols in the form of an extract.
  • the compositions of the invention comprise one or more clerodadienols in the form of an extract from a plant material derived from Vitex Agnus-Castus.
  • the plant material preferably comprises or consists of fruit, leaves, flowers and/or seeds preferably fruit and/or leaf, most preferably fruit.
  • the composition comprises one or more clerodadienols in the form of a Vitex Agnus- Castus extract, preferably a Vitex Agnus-Castus fruit extract.
  • Suitable extracts can be produced with polar solvents, such as with water, with alcohols, such as methanol, ethanol and mixtures thereof, or with water-alcohol mixtures.
  • the extract is produced with a solvent having a relative polarity of more than 0.5, such as more than 0.6 or more than 0.7.
  • Preferred extracts can be produced with water, alcohol, such as methanol, ethanol, propanol or mixtures thereof, or water-alcohol mixtures, preferably with a level of alcohol within the range of 10-95 %(v/v), 30-90 %(v/v) or 60-80 %(v/v) as the extraction solvent.
  • the extract is produced with water, methanol, ethanol or water- ethanol or water-methanol mixtures.
  • the extract is produced with water, ethanol, or water-ethanol mixtures.
  • the extract is produced with a water-ethanol mixture.
  • the extract is produced with a water-ethanol mixture with a level of ethanol within the range of 20-90 %(v/v), preferably within the range of 40-90 %(v/v), preferably within the range of 60-80 %(v/v), preferably within the range of 65-75 %(v/v).
  • Highly preferred extracts can be produced with water as the sole/main extraction solvent.
  • the composition comprises one or more clerodadienols in the form of an aqueous extract, preferably a 100% water extract of a clerodadienol comprising plant material as described above.
  • a composition as defined herein comprising an aqueous extract, preferably a 100% water extract of a clerodadienol comprising plant material.
  • the composition comprises one or more clerodadienols in the form of an aqueous extract, preferably a 100% water extract which is a Vitex agnus-castus extract, preferably a Vitex agnus-castus fruit extract, wherein the extraction was performed at a temperature of more than 60°C, preferably more than 80°C, most preferably more than 95°C.
  • Clerodadienol containing plant extracts may typically comprise one, two, three, four or five additional active ingredients selected from the group consisting of limolene, cineole, pinene, sabinene, aucubin, agnoside, casticin, kaempferol, quercetagetin, orientin, isovitexin, oileic acid, linolenic acid, palmitic acid and stearic acid.
  • the composition comprises a clerodadienol containing plant extract, having a clerodadienol level of at least 0.001 wt.%, based on total essential oil weight, e.g. at least 0.005 wt.%, at least 0.01 wt.%, at least 0.05 wt.%, at least 0.1 wt.%, at least 0.5 wt.% or at least 1 wt.%.
  • the composition comprises a clerodadienol containing plant extract obtainable by aqueous extraction, preferably by extraction with water as the sole extraction solvent (referred to herein as a‘100% water extraction’), performed in such a way that an extract is produced that, excluding any extraction solvent, is from 1/5 - 1/3 of the (dry) weight of the plant material before extraction.
  • the composition comprises a cloredadienol containing plant extract obtainable by a method comprising the steps of: a) providing Vitex agnus-castus plant material, preferably Vitex agnus-castus fruit; b) macerating or grinding the plant material provided in step a);
  • Extracts suitable for use in the context of the present invention, and the production thereof, have been described in the prior art, e.g. in
  • Clerodadienol containing extracts suitable for use in the context of the present invention are available commercially, e.g. from the company“Plantex S.A.” in France under the reference“Chaste tree dry extract PR449”.
  • compositions as defined herein are provided further comprising crocin.
  • Crocin is a naturally occurring compound belonging to the class of carotenoids. It has CAS Registry Number 42553-65-1.
  • the Systematic (lUPAC) name is Bis[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-( ⁇ [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy ⁇ methyl)tetrahydro-2H-pyran-2-yl]
  • Crocin has the following molecular structure: Crocin is the diester formed from the disaccharide gentiobiose and the dicarboxylic acid crocetin. Other monoglycosyl or diglycosyl esters of crocetin are known and often found together with crocin. The group of monoglycosyl or diglycosyl esters of crocetin are referred to as“crocins”.
  • Crocins occur naturally in various plants and herbs, such as Gardenia jasminoides and crocus sativus. Crocin is a non-volatile organic compound contributing to the red colour of saffron, which are stigma of crocus sativus. Together, the monoglycosyl or diglycosyl esters of crocetin constitute about 10% of saffron.
  • crocins may be obtained by extraction or isolation from a natural source or by chemical synthesis.
  • the compositions of the invention comprise one or more crocins, preferably crocin in the form of an extract.
  • the compositions of the invention comprise one or more crocins, preferably crocin in the form of an extract from a plant material derived from Gardenia jasminoides or crocus sativus, preferably from crocus sativus, more preferably from Crocus sativus (L.) Iridaceae.
  • the plant material may consist of the entire plant, but preferably comprises or consists of the plant devoid of root, preferably comprises or consists of leaves and flowers, preferably comprises or consists of flowers, preferably comprises or consists of stigma.
  • the composition comprises one or more crocins, preferably crocin in the form of a Crocus sativus extract, preferably a Crocus sativus leaf or flower extract, more preferably a Crocus sativus flower extract, most preferably a Crocus sativus stigma extract such as a Crocus sativus (L.) Iridaceae stigma extract.
  • the composition comprises one or more crocins, preferably crocin in the form of a Gardenia jasminoides extract, preferably a Gardenia jasminoides fruit extract.
  • Suitable extracts can be produced with polar solvents, such as with water, methanol, ethanol, acetonitrile, diethylether and mixtures thereof.
  • the extract is produced with a solvent having a relative polarity of more than 0.5, such as more than 0.6 or more than 0.7.
  • the extract is produced with water, methanol, ethanol, a water-ethanol mixture or a water-methanol mixture.
  • the extract is produced with water, water-ethanol, or water-methanol mixtures.
  • the extract is produced with water-ethanol or water-methanol mixtures.
  • the extract is produced with a water-methanol or a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v).
  • the extract is produced using 30-70 gram plant material per liter extraction solvent, preferably 40-60 g/l, most preferably 45-55 g/l.
  • the extract is produced using microsimultaneous hydro distillation- extraction (MSDE) and/or ultrasound-assisted extraction (USE).
  • MSDE microsimultaneous hydro distillation- extraction
  • USE ultrasound-assisted extraction
  • the extract is produced with supercritical carbon dioxide.
  • the plant material is heated prior to extraction, for example at a temperature above 50°C, preferably above 70°C, such as 80°C for at least 1 minute, preferably at least 20 minutes, preferably at least 1 hour.
  • the composition comprises one or more crocins, preferably crocin in the form of a water- alcohol extract of a crocin comprising plant material.
  • a composition as defined herein comprising a water, a water-ethanol or a water- methanol extract, preferably a water-ethanol extract of a crocin containing plant material.
  • the composition comprises crocin in the form of a water-ethanol extract produced with a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v), from Crocus sativus, preferably from Crocus sativus leaf or flower, more preferably from Crocus sativus flower, most preferably from Crocus sativus stigma, such as from Crocus sativus (L.) Iridaceae stigma.
  • the composition comprises crocin in the form of a water-ethanol extract wherein the extraction was performed at a temperature of less than 90°C, preferably less than 60°C, most preferably less than 40°C.
  • the one or more crocins may typically comprise one, two, three, four or five additional compounds selected from the group consisting of safranal, picrocrocin, kaempherol, further crocins, crocetin, pinene, cineol, riboflavin, quercetin, lycopene, alpha carotene, beta carotene, zeaxanthin, phytoene, and phytofluene.
  • the composition comprises one or more crocins, preferably a crocin containing plant extract having a total crocins content of at least 0.1 wt.%, based on total weight of the extract after solvent evaporation, e.g.
  • the composition comprises a crocin containing plant extract obtainable by water-ethanol extraction employing a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v) as the extraction solvent, wherein the extraction is performed in such a way that an extract is produced that, excluding any extraction solvent, is from 1/6 - 1/4 of the (dry) weight of the plant material before extraction.
  • the composition comprises a crocin containing plant extract obtainable by a method comprising the steps of:
  • Crocus sativus plant material preferably a Crocus sativus leaf or flower, more preferably Crocus sativus flower, most preferably Crocus sativus stigma such as a Crocus sativus (L.) Iridaceae stigma;
  • step b) preferably macerating or grinding the plant material provided in step a);
  • c) performing an extraction with a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v), preferably at a temperature of less than 90°C, preferably less than 60°C, most preferably less than 40°C.; d) concentrating the extract, preferably at a temperature not exceeding 70°C, preferably not exceeding 60°C, preferably not exceeding 45°C; and
  • Extracts suitable for use in the context of the present invention, and the production thereof, have been described in the prior art, e.g. in
  • Crocin containing extracts suitable for use in the context of the present invention are available commercially, e.g. from the company“Activ’lnside” in France under the reference“Safr’inside PR-0033”.
  • compositions as defined herein are provided further comprising safranal.
  • Safranal is a naturally occurring cyclical terpenic aldehyde. It has CAS Registry Number 116-26-7.
  • the Systematic (lUPAC) name is 2,6,6-trimethyl-1 ,3-cyclohexadiene- 1-carboxaldehyde. Safranal has the following molecular structure:
  • safranal occurs naturally in various plants, such as aspalathus linearis, camellia sinensis, crocus sativus, ficus carica and lyceum chinense, cuminum cyminum, centaurea sibthorpii, centaurea amanicola, centaurea consanguinea, erodium cicutarium, calycopteris floribunda, sambucus nigra, citrus limon, achillea distans. Safranal is the most abundant chemical in saffron essential oil and accounts for 60-70% of the volatile fraction.
  • safranal may be obtained by extraction or isolation from a natural source or by chemical synthesis.
  • the compositions of the invention comprise safranal in the form of an extract.
  • the compositions of the invention comprise safranal in the form of an extract from a plant material derived from one or more of the plant species recited here above, preferably from the group consisting of as aspalathus linearis, camellia sinensis, crocus sativus, ficus carica and lyceum chinense, preferably from Crocus sativus more preferably from Crocus sativus (L.) Iridaceae.
  • the plant material may consist of the entire plant, but preferably comprises or consists of the plant devoid of root, preferably comprises or consists of leaves and flowers, preferably comprises or consists of flowers, preferably comprises or consists of stigma.
  • the composition comprises safranal in the form of a Crocus sativus extract, preferably a Crocus sativus leaf or flower extract, more preferably a Crocus sativus flower extract, most preferably a Crocus sativus stigma extract such as a Crocus sativus (L.) Iridaceae stigma extract.
  • Suitable extracts can be produced with polar solvents, such as with water, methanol, ethanol, acetonitrile and mixtures thereof.
  • the extract is produced with a solvent having a relative polarity of more than 0.5, such as more than 0.6 or more than 0.7.
  • the extract is produced with water, methanol, ethanol or water-ethanol or water-methanol mixtures. In more preferred embodiments, the extract is produced with water, water-ethanol, or water-methanol mixtures. Most preferably, the extract is produced with water-ethanol or water-methanol mixtures.
  • the extract is produced with a water-methanol or a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v).
  • the extract is produced using 30-70 gram plant material per liter extraction solvent, preferably 40-60 g/l, most preferably 45-55 g/l.
  • the extract is produced using microsimultaneous hydro distillation- extraction (MSDE) and/or ultrasound-assisted extraction (USE).
  • MSDE microsimultaneous hydro distillation- extraction
  • USE ultrasound-assisted extraction
  • the extract is produced with supercritical carbon dioxide.
  • the plant material is heated prior to extraction, for example at a temperature above 50°C, preferably above 70°C, such as 80°C for at least 1 minute, preferably at least 20 minutes, preferably at least 1 hour.
  • the composition comprises safranal in the form of a water-alcohol extract of a safranal comprising plant material.
  • a composition as defined herein comprising a water, a water-ethanol or a water-methanol extract, preferably a water-ethanol extract of a safranal containing plant material.
  • the composition comprises safranal in the form of a water-ethanol extract produced with a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), more preferably within the range of 20-40 %(v/v), still more preferably within the range of 25-35 %(v/v), most preferably within the range of 28-32 %(v/v), from Crocus sativus, preferably from Crocus sativus leaf or flower, more preferably from Crocus sativus flower, most preferably from Crocus sativus stigma, such as Crocus sativus (L.) Iridaceae stigma.
  • the composition comprises safranal in the form of a water-ethanol extract produced, wherein the extraction was performed at a temperature of less than 90°C, preferably less than 60°C, most preferably less than 40°C.
  • the safranal containing plant extracts may typically comprise one, two, three, four or five additional compounds selected from the group consisting of picrocrocin, kaempherol, crocins such as crocin, crocetin, pinene, cineol, riboflavin, quercetin, lycopene, alpha carotene, beta carotene, zeaxanthin, phytoene, and phytofluene.
  • picrocrocin kaempherol
  • crocins such as crocin, crocetin, pinene, cineol, riboflavin, quercetin, lycopene, alpha carotene, beta carotene, zeaxanthin, phytoene, and phytofluene.
  • the composition comprises a safranal containing plant extract, having a safranal content of at least 0.1 %, based on total volatiles content, e.g. at least 1 %, at least 5 %, at least 10 %, at least 30 %, at least 50 % or at least 60 %.
  • a suitable method to determine the safranal content based on total volatiles content is using gas chromatography-mass spectrometry, for example using the method described in Eleonora Urbani, Francesca Blasi, Stephan Chiesi, Angela Maurizi & Lina Cossignani (2015) Characterization of Volatile Fraction of Saffron from Central Italy (Cascia, Umbria), International Journal of Food Properties, 18: 10, 2223-2230.
  • the composition comprises a safranal containing plant extract, having a safranal content of at least 0.1 wt.%, based on total weight of the extract after solvent evaporation, e.g. at least 0.5 wt.%, at least 1 wt.% or at least 1.5 wt.% wherein the safranal content is determined in accordance with ISO 3632- 2:2010.
  • the composition comprises a safranal containing plant extract obtainable from a water-ethanol extraction employing a water- ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v) as the extraction solvent, wherein the extraction is performed in such a way that an extract is produced that, excluding any extraction solvent, is from 1/6 - 1/4 of the (dry) weight of the plant material before extraction.
  • the composition comprises a safranal containing plant extract obtainable by a method comprising the steps of:
  • Crocus sativus plant material preferably a Crocus sativus leaf or flower, more preferably Crocus sativus flower, most preferably Crocus sativus stigma such as a Crocus sativus (L.) Iridaceae stigma;
  • step b) preferably macerating or grinding the plant material provided in step a);
  • c) performing an extraction with a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v), preferably at a temperature of less than 90°C, preferably less than 60°C, most preferably less than 40°C; d) concentrating the extract, preferably at a temperature not exceeding 70°C, preferably not exceeding 60°C, preferably not exceeding 45°C; and
  • Extracts suitable for use in the context of the present invention, and the production thereof, have been described in the prior art, e.g. in
  • Safranal containing extracts suitable for use in the context of the present invention are available commercially, e.g. from the company“Activ’lnside” in France under the reference“Safr’inside PR-0033”.
  • an extract such as the safranal extracts as defined herein, is incorporated in the composition as a source of both crocin as well as safranal.
  • an extract such as the Crocus sativus extracts as defined herein, is incorporated in the composition as a source of both crocin as well as safranal.
  • compositions as defined herein comprising apigenins.
  • Apigenin, 4',5,7-trihydroxyflavone is naturally occurring compound belonging to the class of flavones.
  • Apigenin has the CAS Registry Number 520-36-5 and systematic (lUPAC) name 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one. Common synonyms include Apigenine; Chamomile; Apigenol; Spigenin; Versulin; 4', 5, 7- Trihydroxyflavone and C.l. Natural Yellow 1.
  • Apigenin has the following molecular structure: Apigenin In natural conditions, apigenin predominantly occurs in the form of an apigenin glycoside, wherein apigenin is bound to a sugar through a glycosidic bond.
  • apigenin refers to the aglycone of apigenin glycosides.
  • the plural form, i.e.“apigenins”, is used herein to generically denote apigen and the apigenin glycosides, as will be understood by those skilled in the art.
  • Apigenin and apigenin glycosides occur naturally in various plants, such as plants in the genera artemisia, perilla, urtica, passiflora, camelia, cayaponia, colocasia, desmodium, hordeum, origanum, ocimum, jatropha, parkinsonia, peperomia, piheranthos, centaurea, indigo, bomba, lychnophera, asplenium, chinotto, citrus, viola, trigonella, lamiacea, labiatae, lavandula, nipponanthemum, abrus, santalum, oryza, scleropyrum, tulsi, indigofera, bombax, glinus, lychnophora, urticaceae, rosales, malpighiales, thymus, prunus, camellia, olea, brassica, apium, petroselinum, matricaria, chamae
  • Plants of particular interest as an apigenin or apigenin glycoside source are vitex agnus-castus, petroselinum crispum, apium graveolens, citrus paradisi, citrus maxima, perilla frutescens, Matricaria chamomilla, chrysanthemum morifolium and chamaemelum nobile, and in particular matricaria recutita (also known as Matricaria chamomilla); chamaemelum nobile; and chrysanthemum morifolium.
  • Apigenin or apigenin glycosides are particularly abundant in the flowers of chamomile plants, constituting up to 68% of total flavonoids. In most camomille plant varieties, apigenin-7-O-glucoside is the dominant form and is present in about 100-500mg/100g flowers, while apigenin is present in an amount of about 5-25mg/100g flowers.
  • compositions of the invention comprise apigenin or an apigenin glycoside, preferably an apigenin glycoside selected from the group consisting of apigenin 7-O-apioglucoside (apiin), apigenin 7-O-glucoside (apigetrin), apigenin 8-C- glucoside (vitexin), apigenin 6-C-glucosid (isovitexin), apigenin 7-O-neohesperidoside (rhoifolin), or apigenin 6-C-glucoside 8-C-arabinoside (schaftoside), preferably apigenin 7-O-apioglucoside (apiin) or apigenin 7-O-glucoside (apigetrin), most preferably apigenin 7-O-glucoside.
  • the apigenin or apigenin glycoside commonly exists in an acetylated form, such as a monoacetylated or diacetylated form.
  • the compositions and extracts described herein comprise acetylated apigenin or apigenin glycoside.
  • Apigenin and/or apigenin glycosides may be obtained by extraction or isolation from a natural source or by chemical synthesis.
  • compositions of the invention comprise apigenin or an apigenin glycoside in the form of an extract.
  • compositions of the invention comprise apigenin or an apigenin glycoside in the form of an extract from a plant material derived from a plant species in a genus selected from the group consisting of artemisia, perilla, urtica, passiflora, camelia, cayaponia, colocasia, desmodium, hordeum, origanum, ocimum, jatropha, parkinsonia, peperomia, piheranthos, centaurea, indigo, bomba, lychnophera, asplenium, chinotto, citrus, viola, trigonella, lamiacea, labiatae, lavandula, nipponanthemum, abrus, santalum, oryza, scleropyrum, tulsi, indigofera, bombax, glinus
  • compositions of the invention comprise apigenin or an apigenin glycoside in the form of an extract from plant material derived from vitex agnus-castus, petroselinum crispum, apium graveolens, citrus paradisi, citrus maxima, perilla frutescens, Matricaria chamomilla, chrysanthemum morifolium or chamaemelum nobile, preferably the compositions of the invention comprise apigenin or an apigenin glycoside in the form of an extract from plant material derived from matricaria recutita (also known as Matricaria chamomilla), chamaemelum nobile, or chrysanthemum morifolium.
  • the plant material preferably comprises or consists of leaves and flowers, preferably flowers, preferably the ray florets.
  • the extract is a flower extract, preferably an extract of the flowers, preferably the ray florets of matricaria recutita (also known as Matricaria chamomilla), chamaemelum nobile, or chrysanthemum morifolium, preferably an extract of the flowers, preferably the ray florets of matricaria recutita (also known as Matricaria chamomilla).
  • Suitable extracts can be produced with polar solvents, such as with water, methanol, ethanol and mixtures thereof.
  • the extract is produced with a solvent having a relative polarity of more than 0.5, such as more than 0.6 or more than 0.7 or more than 0.8.
  • Preferred extracts can be produced with water, methanol, ethanol, propanol or mixtures thereof, preferably with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v).
  • the extract is produced with water, methanol, ethanol or water-ethanol or water-methanol mixtures.
  • the extract is produced with water, ethanol, or water- methanol mixtures. Most preferably, the extract is produced with water-ethanol mixtures.
  • the extract is produced with a water-ethanol mixture with a level of ethanol within the range 10-60 %(v/v), preferably within the range of 20-40 %(v/v), preferably within the range of 25-35 %(v/v), preferably within the range of 28-32 %(v/v).
  • the composition comprises apigenin or an apigenin glycoside in the form of a water, methanol, ethanol, propanol or mixtures thereof of an apigenin or an apigenin glycoside comprising plant material, preferably a water-ethanol extract.
  • a composition as defined herein comprising a water, methanol, ethanol or water- ethanol or water-methanol extract of an apigenin or an apigenin glycoside containing plant material, preferably a water-ethanol extract.
  • the extract is rich in apigenin-7-O-glucoside and contains more apigenin-7-O-glucoside than apigenin.
  • the extract is rich in apigenin-7-O- glucoside and more than 20%, preferably more than 30%, more than 50%, more than 70% of the apigenin and apigenin-glycoside content is apigenin-7-O-glucoside.
  • Such apigenin- 7-O-glucoside rich extracts can be produced with water, ethanol or methanol as the extraction medium, preferably water or ethanol.
  • the extract is rich in apigenin and contains more apigenin than apigenin-7-O-glucoside.
  • the extract is rich in apigenin and more than 10%, preferably more than 20%, more than 50%, more than 70% of the apigenin and apigenin-glycoside content is apigenin.
  • Such apigenin rich extracts can be produced with water-ethanol or water-methanol mixtures, preferably water-ethanol mixtures, preferably with a level of alcohol lower than 50 %(v/v), preferably lower than 40 %(v/v), preferably lower than 30 %(v/v).
  • flavonoid yield of such extracts rich in apigenin may be lower than the flavonoid yield of extracts rich in apigenin-7-O-glucoside, the relative increase of apigenin content may be desirable since apigenin is believed to be more physiologically active than apigenin glycosides.
  • the composition comprises apigenin or apigenin-glycoside in the form of a water-ethanol extract produced with a water-ethanol mixture with a level of alcohol within the range of 10-60 %(v/v), preferably within the range of 20-40 %(v/v), more preferably within the range of 25-35 %(v/v), most preferably within the range of 28-32 %(v/v), from a flower, preferably a ray floret, of matricaria recutita (also known as Matricaria chamomilla), chamaemelum nobile, or chrysanthemum morifolium, preferably of matricaria recutita.
  • matricaria recutita also known as Matricaria chamomilla
  • chamaemelum nobile or chrysanthemum morifolium
  • the apigenin or apigenin-glycoside containing plant extracts may typically comprise one, two, three, four or five additional active ingredients selected from the group consisting of hyperoside, herniarin, umbelliferone, chlorogenic acid, caffeic acid, luteolin, luteolin-7-O-glucoside, quercetin, rutin, and naringenin.
  • the apigenin or apigenin-glycoside containing plant extracts may typically be prepared by milling, crushing or grinding plant material as described herein earlier, and suspending the plant material in the extraction medium, for example at a concentration of 0.01-50 %(w/v) of fresh plant material, preferably 0.1-20 %(w/v), preferably 0.5-10 %(w/v), preferably 1-7 %(w/v), preferably 2-6 %(w/v).
  • the composition comprises an apigenin or apigenin-glycoside containing plant extract, having a total amount of apigenin and apigenin-glycosides of at least 0.1 wt.%, based on the weight of the apigenin or apigenin- glycoside containing plant extract essentially free of extraction solvent, e.g. at least 0.5 wt.%, at least 1 wt.%, at least 1.5 wt.%, at least 2 wt.% or at least 5 wt.%, preferably as determined in accordance with the method described in the USP chamomile monograph.
  • the composition comprises an apigenin or apigenin-glycoside containing plant extract obtainable by a method comprising the steps of:
  • Matricaria recutita also known as Matricaria chamomilla
  • plant material preferably Matricaria recutita flowers, preferably Matricaria recutita ray florets
  • step b) preferably macerating or grinding the plant material provided in step a);
  • Extracts suitable for use in the context of the present invention, and the production thereof, have been described in the prior art, e.g. in
  • Apigenin containing extracts suitable for use in the context of the present invention are available commercially, e.g. from the company“Evear extraction soilutions” in France under the reference“Chamomile dry extract 5% apigenin E2423A5”.
  • the composition further comprises vitamin D.
  • Vitamin D is a fat soluble vitamin that is rarely found naturally in food. It is not a true vitamin, but is a steroid prohormone that is produced in the skin by ultraviolet sunlight and converted by a series of hydroxylations to a biologically active steroid hormone metabolite.
  • An active metabolite of vitamin D is calcitriol.
  • “vitamin D” comprises a group of, but not limited to, ergocalciferol (D2), cholecalciferol (D3), calcidiol (25 hydroxy vitamin D), or calcitriol (1 ,25 di hydroxy vitamin D). Because vitamin D is lipid soluble and potentially toxic, oral intakes of vitamin D greater than 1000 IU have not been advised.
  • the composition further comprises vitamin D3.
  • the composition further comprises magnesium.
  • Suitable magnesium sources may comprise any pharmaceutically acceptable inorganic or organic compound containing magnesium such as magnesium carbonate, magnesium hydroxide, magnesium gluconate, magnesium oxide, magnesium citrate or magnesium lactate; preferably magnesium carbonate or magnesium hydroxide, most preferably magnesium carbonate.
  • Magnesium carbonate is preferably provided in the form of the dypingite mineral. Current guidelines in the US provide a recommended daily amount of magnesium of 300 - 400 mg (for adult women). It has been well established that magnesium contributes to increased hepatic metabolism. The present inventors believe that the increased hepatic effect of magnesium increases the sympathetic effects of the vicenin-2, as well as rosmarinic acid and allows for increased adsorption.
  • the composition comprises magnesium in the form of magnesium carbonate.
  • Magnesium sources suitable for use in the context of the present invention are available commercially, e.g. from the company “Magnesia” in Germany under the reference“Magnesia 81811”.
  • compositions as defined herein comprising:
  • the weight to weight ratio of said Perilla extract to said Vitex agnus-castus extract is 50:1 to 1 :50, determined based on extract weights essentially free of extraction solvent, preferably 25:1 to 1 :25, more preferably 15:1 to 1 :15, most preferably 5:1 to 1 :1.
  • the weight to weight ratio of said Perilla extract to said Crocus sativus extract is 50: 1 to 1 :50, determined based on extract weights essentially free of extraction solvent, preferably 25: 1 to 1 :25, more preferably 15:1 to 1 : 15, most preferably 5:1 to 1 : 1.
  • the weight to weight ratio of said Perilla extract to said Matricaria chamomilla extract is 50: 1 to 1 :50, determined based on extract weights essentially free of extraction solvent, preferably 25:1 to 1 :25, more preferably 10: 1 to 1 :10, most preferably 2: 1 to 1 :2.
  • compositions as defined herein are preferably provided in the form of a pharmaceutical formulation or a nutraceutical formulation, which may also be referred to as a food supplement or food supplement formulation.
  • the invention provides a pharmaceutical or nutraceutical formulation in the form of a so-called ‘unit dosage form’, in particular a unit dosage form that is suitable for oral administration.
  • unit dosage form refers to a physically discrete unit of the pharmaceutical or nutraceutical formulation comprising a fixed, pre-determined dose of the pharmaceutically and/or physiologically active ingredient(s) in a form suitable for administration to a subject in need thereof.
  • a unit dosage form comprises vicenin-2 in an amount of 0.005 mg or more, preferably 0.01 mg or more, preferably 0.05 mg or more and/or in an amount of 10 mg or less, preferably 5 mg or less, preferably 1 mg or less.
  • a unit dosage form comprises rosmarinic acid in an amount of 0.005 mg or more, preferably 0.01 mg or more, preferably 0.05 mg or more and/or in an amount of 10 mg or less, preferably 5 mg or less, preferably 1 mg or less.
  • a unit dosage form comprises a clerodadienol in an amount of 0.005 mg or more, preferably 0.01 mg or more, preferably 0.05 mg or more and/or in an amount of 10 mg or less, preferably 5 mg or less, preferably 1 mg or less.
  • a unit dosage form comprises crocin in an amount of 0.01 mg or more, preferably 0.1 mg or more, preferably 0.4 mg or more and/or in an amount of 5 mg or less, preferably 3 mg or less, preferably 1.5 mg or less.
  • a unit dosage form comprises safranal in an amount of 0.01 mg or more as determined in accordance with ISO 3632-2:2010, preferably 0.1 mg or more, preferably 0.2 mg or more and/or in an amount of 5 mg or less as determined in accordance with ISO 3632-2:2010, preferably 3 mg or less, preferably 1.5 mg or less.
  • a unit dosage form comprises apigenin or an apigenin glycoside in an amount of 0.1 mg or more as determined in accordance with the method described in the USP chamomile monograph, preferably 0.5 mg or more, preferably 1.5 mg or more and/or in an amount of 15 mg or less in accordance with the method described in the USP chamomile monograph, preferably 10 mg or less, preferably 4 mg or less.
  • a unit dosage form comprises vitamin D, preferably vitamin D3 in an amount of 0.01 mg or more, preferably 0.1 mg or more, preferably 1 mg or more and/or in an amount of 20 mg or less, preferably 10 mg or less, preferably 2 mg or less.
  • a unit dosage form comprises vitamin D, preferably vitamin D3 in an amount of 0.1 pg or more, preferably 0.6 pg or more, preferably 1 pg or more and/or in an amount of 40 pg or less, preferably 15 pg or less, preferably 4 pg or less.
  • a unit dosage form comprises vitamin D, preferably vitamin D3 in an amount corresponding to 4 IU or more, preferably 24 IU or more, preferably 40 IU or more and/or in an amount corresponding to 1200 IU or less, preferably 600 IU or less, preferably 160 I U or less.
  • a unit dosage form comprises a magnesium compound, preferably magnesium carbonate, preferably magnesium carbonate in the form of the dypingite mineral in an amount of 10 mg or more, preferably 100 mg or more, preferably 550 mg or more and/or in an amount of 2000 mg or less, preferably 1000 mg or less, preferably 650 mg or less.
  • Perilla frutescens seed extract in an amount of 5 mg or more, preferably 20 mg or more, preferably 30 mg or more and/or in an amount of 150 mg or less, preferably 75 mg or less, preferably 55 mg or less, such as 30 mg, 35 mg, 40 mg, 45 mg or 50 mg;
  • Vitex agnus-castus fruit extract in an amount of 0.5 mg or more, preferably 2 mg or more, preferably 10 mg or more and/or in an amount of 100 mg or less, preferably 50 mg or less, preferably 20 mg or less, such as 5 mg, 10 mg, 13 mg, 15 mg or 17 mg; • Crocus sativus stigma extract in an amount of 0.5 mg or more, preferably 2 mg or more, preferably 5 mg or more and/or in an amount of 80 mg or less, preferably 30 mg or less, preferably 15 mg or less, such as 3 mg, 6 mg, 8 mg, 9 mg or 1 1 mg;
  • Matricaria chamomilla flower extract in an amount of 5 mg or more, preferably 20 mg or more, preferably 30 mg or more and/or in an amount of 150 mg or less, preferably 75 mg or less, preferably 60 mg or less, such as 30 mg, 35 mg, 40 mg, 45 mg or 55 mg;
  • vitamin D preferably vitamin D3 in an amount of 0.01 mg or more, preferably 0.1 mg or more, preferably 1 mg or more and/or in an amount of 20 mg or less, preferably 10 mg or less, preferably 2 mg or less;
  • a magnesium compound preferably magnesium carbonate, preferably magnesium carbonate in the form of the dypingite mineral in an amount of 10 mg or more, preferably 100 mg or more, preferably 550 mg or more and/or in an amount of 2000 mg or less, preferably 1000 mg or less, preferably 650 mg or less.
  • said composition comprises the vitamin D, preferably vitamin D3, in an amount of 0.1 pg or more, preferably 0.6 pg or more, preferably 1 pg or more and/or in an amount of 40 pg or less, preferably 15 pg or less, preferably 4 pg or less.
  • compositions as defined herein are preferably provided in a form suitable for oral administration.
  • oral formulations include tablets, capsules, lozenges as well as particulates, such as granulates and powders, typically contained in a unit dosage packaging, such as a sachet.
  • the pharmaceutical and/or nutraceutical formulation is a liquid suitable for oral administration, such as a syrup, elixir or the like, e.g. contained in a (unit dosage) vial or ampoule or in a bottle or flask (from which a single unit dose must be drawn).
  • the unit dosage form is a solid oral unit dosage formulation, more preferably a tablet or capsule suitable for oral administration.
  • a solid oral unit dosage formulation more preferably a tablet or capsule suitable for oral administration.
  • the unit dosage form is a tablet for oral administration.
  • Tablets that can suitably be used for the purposes of the present invention typically comprise a core, comprising a combination of pharmacologically and/or physiologically active components as specified herein elsewhere in conjunction with one or more conventional excipients needed to (e.g.) facilitate processing of said combination into a tablet core that remains intact during processing, storing and distribution, that is convenient for a patient to self-administer and swallow and that disintegrates in the patient’s gastrointestinal tract at the appropriate rate, e.g. as quickly as possible.
  • a core comprising a combination of pharmacologically and/or physiologically active components as specified herein elsewhere in conjunction with one or more conventional excipients needed to (e.g.) facilitate processing of said combination into a tablet core that remains intact during processing, storing and distribution, that is convenient for a patient to self-administer and swallow and that disintegrates in the patient’s gastrointestinal tract at the appropriate rate, e.g. as quickly as possible.
  • the tablet core comprises, besides the combination of pharmacologically and/or physiologically active ingredients, one or more of a bulking agent, such as sorbitol or microcrystalline cellulose, anti-caking agents, such as colloidal silicon, lubricants, such as glyceryl behenate, binders, fillers, disintegrants, preservatives, emollients, humectants, sweetening-agents, plasticizers, film-forming agents, hardness-increasing agents, flavours, etc.
  • a bulking agent such as sorbitol or microcrystalline cellulose
  • anti-caking agents such as colloidal silicon
  • lubricants such as glyceryl behenate
  • binders such as glyceryl behenate
  • fillers such as glyceryl behenate
  • disintegrants such as glyceryl behenate
  • preservatives such as glyceryl behenate
  • emollients such as
  • the tablet core can suitably be produced by direct compression of a (free-flowing) mixture or blend of the combination of pharmacologically and/or physiologically active ingredients and the excipients or by the formation of a granulate comprising the combination of pharmacologically and/or physiologically active ingredients and the excipients, optionally using a granulation liquid, which granulate is subsequently compressed into a tablet (core).
  • the tablets comprise a coating surrounding the core as defined here above. It is conventional in the art to apply a coating on a tablet formulation, in particular in order to improve the visual appearance of the tablet, in order to facilitate swallowing of the tablet, in order to mask unpleasant taste of tablet components, in order to confer a distinctive and recognizable appearance and/or in order to control disintegration of the tablet and release of the active ingredients from the tablet.
  • a coating is applied using conventional coating compositions and techniques, e.g. using coatings comprising film-forming agents, thickener, anticaking agent, lubricant and colorants.
  • kits of parts comprising two or more unit dosage forms as defined herein, optionally provided with instructions for use of the unit dosage forms in a treatment regimen as defined herein.
  • a kit may comprise a plurality of unit dosage forms, such as 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90 or 100 unit dosage forms, said unit dosage forms preferably being adapted for daily administration of 1 , 2, 3 or 4 unit dosage forms.
  • the kit contains a packaging and/or a leaflet reflecting said schedule of administration.
  • kit packet comprises 60 unit dosage forms for once daily administration of 2 unit dosage forms over a period of 30 days.
  • said kit of parts further comprises printed instructions for using the product in the treatment a subject as defined herein, by administering unit dosage forms contained in the kit according to the regimens defined herein.
  • a further aspect of the invention is directed to, stated generally, the prophylactic or curative treatment of a medical or non-medical condition in a subject in need thereof, using the compositions as defined herein before.
  • the compositions of the invention are useful for treatment of medical and non-medical conditions, especially conditions that may benefit from the administration of compositions as described herein, such as premenstrual syndrome and/or menstrual discomfort.
  • the treatment comprises administering to the subject an effective amount of a composition as described herein elsewhere.
  • premenstrual syndrome also referred to as ‘PMS’
  • PMS menstrual syndrome
  • the severity of symptoms associated with PMS range from mild to incapacitating and it has been estimated that up to 90% of women who menstruate suffer from some degree of PMS, while 20-40% suffer symptoms severe enough to lead to physical or mental incapacitation. The severity of symptoms can vary from month to month or year to year for a particular woman.
  • Symptoms associated with PMS typically include depression, anger, irritability, anxiety, bloating, weight gain, abdominal pain, muscles and/or joint pain, breast pain and swelling, headache, fatigue, difficulty sleeping, difficulty concentrating, confusion, food cravings, lack of sexual interest and/or decreased efficiency.
  • menstrual discomfort encompasses conditions associated with the female menstrual cycle involving a variety of physical and mental symptoms, which symptoms typically peak during menses of a woman's cycle. Said symptoms include for example abdominal pain, back pain, cramps, breast tenderness, mood changes, headaches, nausea and/or dizziness. The severity of these symptoms ranges from mild to incapacitating.
  • the invention provides compositions as defined herein, for use in the treatment, in particular the prophylactic or curative treatment, of a subject in need thereof, especially a subject suffering from premenstrual syndrome and/or menstrual discomfort.
  • said method comprises the treatment, prevention or alleviation of a symptom associated with premenstrual syndrome and/or menstrual discomfort.
  • the invention provides compositions as defined herein, for use in the treatment, in particular the prophylactic or curative treatment, of a condition, especially a condition selected from premenstrual syndrome and menstrual discomfort, in a subject in need thereof.
  • the invention provides compositions as defined herein, for use in the treatment, in particular the prophylactic or curative treatment, of a symptom associated with a condition, especially premenstrual syndrome and/or menstrual discomfort, in a subject in need thereof.
  • the invention provides compositions as defined herein, for use in the prevention, treatment or alleviation of a symptom associated with a condition, especially premenstrual syndrome and/or menstrual discomfort, in a subject in need thereof.
  • the invention provides a method of treatment, in particular the prophylactic or curative treatment, of a subject in need thereof, especially a subject suffering from premenstrual syndrome and/or menstrual discomfort, said treatment comprising the administration of a composition as defined herein.
  • said method comprises the treatment, prevention or alleviation of a symptom associated with a condition selected from premenstrual syndrome and menstrual discomfort.
  • the invention provides a method of treatment, in particular the prophylactic or curative treatment, of a condition, especially premenstrual syndrome and/or menstrual discomfort, in a subject in need thereof, said method comprising the administration of a composition as defined herein.
  • the invention provides a method of treatment, in particular the prophylactic or curative treatment, of a symptom associated with a condition, especially premenstrual syndrome and/or menstrual discomfort, in a subject in need thereof, said method comprising the administration of a composition as defined herein.
  • the invention provides a method of preventing, treating and/or alleviating a symptom associated with a condition, especially premenstrual syndrome and/or menstrual discomfort, in a subject in need thereof, said method comprising the administration of a composition as defined herein.
  • Main symptoms of premenstrual symptoms and/or menstrual discomfort to be treated, alleviated and/or prevented in accordance with the invention disclosed herein can be divided in three main categories, notably breast symptoms, psychological/mental symptoms and abdominopelvic symptoms.
  • the symptom associated with premenstrual syndrome and/or menstrual discomfort is a breast symptom, preferably a symptom selected from painful breast, tense breast, mastodynia, and combinations thereof.
  • the symptom associated with premenstrual syndrome and/or menstrual discomfort is a psychological symptom, preferably a psychological symptom selected from irritability, anxiety, depression, and combinations thereof.
  • the symptom associated with premenstrual syndrome and/or menstrual discomfort is an abdominopelvic symptom, preferably an abdominopelvic symptom selected from bloating, cramps, transit problems, and combinations thereof.
  • an abdominopelvic symptom selected from bloating, cramps, transit problems, and combinations thereof.
  • the term "curative treatment”, in relation a given condition includes, but is not limited to, arresting the development of the condition; relieving the condition, causing regression of the condition; or relieving a symptom caused by or resulting from the condition.
  • prophylactic treatment in relation to a given condition means preventing the onset of development of the condition if none had occurred, or preventing the condition from occurring in a subject that may be predisposed to the condition but has not yet been diagnosed as having the condition.
  • subject refers to an animal, in particular a human, that is treatable by the method of the invention.
  • subject refers to both the male and female gender unless one gender is specifically indicated.
  • the invention is directed specifically to the treatment of premenstrual syndrome and/or menstrual discomfort and/or symptoms thereof and/or conditions associated therewith, it will be understood that the subject is a female.
  • the subject is a human subject.
  • the subject in need thereof is a subject suffering from or at risk of suffering from any one of the conditions as defined here above.
  • the subject in need thereof is a subject suffering from or at risk of suffering from premenstrual syndrome and/or menstrual discomfort.
  • the human subject can be a juvenile, an adolescent, an adult or an elderly subject.
  • the human subject is at least 18 years of age, preferably at least 25 years, at least 30 years, at least 35 years, at least 40 years or at least 45 years.
  • Human subjects treated in accordance with the invention will typically be less than 65 years of age, less than 60 years of age or less than 55 years of age.
  • the methods as described herein comprise the step of identifying a subject that is in need of receiving treatment with the compositions of the invention and/or identifying a subject suffering from or at risk of suffering from any of the conditions as described here above and/or a subject meeting any of the above- described physiological characteristics as described here above.
  • such method of treatment is carried out for non-medical or non- therapeutic reasons.
  • Such treatment of healthy subjects for non-medical reasons will typically rely on the use of the same compositions and products and the same routes of administration and the same dosage regimens as defined here above in relation to medical treatments.
  • the subject is a healthy subject.
  • the methods as described herein comprise the administration to the subject in need thereof of a composition or product as described herein in an amount effective to prevent or treat one or more of the conditions or pathologies as defined herein.
  • the treatment comprises the administration of vicenin-2 in an average daily dose of 0.01 mg or more, preferably 0.02 mg or more, preferably 0.1 mg or more and/or in an amount of 20 mg or less, preferably 10 mg or less, preferably 2 mg or less.
  • the treatment comprises the administration of rosmarinic acid in an average daily dose of 0.01 mg or more, preferably 0.02 mg or more, preferably 0.1 mg or more and/or in an amount of 20 mg or less, preferably 10 mg or less, preferably 2 mg or less.
  • the treatment comprises the administration of Perilla frutescens seed extract in an average daily dose of 10 mg or more, preferably 40 mg or more, preferably 60 mg or more and/or in an amount of 300 mg or less, preferably 150 mg or less, preferably 110 mg or less, such as 60 mg, 70 mg, 80 mg, 90 mg or 100 mg.
  • the treatment comprises the administration of a clerodadienol in an average daily dose of 0.01 mg or more, preferably 0.02 g or more, preferably 0.1 mg or more and/or in an amount of 20 mg or less, preferably 10 mg or less, preferably 2 mg or less.
  • the treatment comprises the administration of Vitex agnus-castus fruit extract in an average daily dose of 1 mg or more, preferably 4 mg or more, preferably 20 mg or more and/or in an amount of 200 mg or less, preferably 100 mg or less, preferably 40 mg or less, such as 10 mg, 20 mg, 26 mg, 30 mg or 34 mg.
  • the treatment comprises the administration of crocin in an average daily dose of 0.01 mg or more, preferably 0.1 mg or more, preferably 0.4 mg or more and/or in an amount of 5 mg or less, preferably 3 mg or less, preferably 1.5 mg or less.
  • the treatment comprises the administration of safranal in an average daily dose of 0.02 mg or more as determined in accordance with ISO 3632-2:2010, preferably 0.2 mg or more, preferably 0.4 mg or more and/or in an amount of 10 mg or less as determined in accordance with ISO 3632-2:2010, preferably 6 mg or less, preferably 3 mg or less.
  • the treatment comprises the administration of Crocus sativus stigma extract in an average daily dose of extract of 1 mg or more, preferably 4 mg or more, preferably 10 mg or more and/or in an amount of extract of 160 mg or less, preferably 60 mg or less, preferably 30 mg or less, such as 6 mg, 12 mg, 16 mg, 18 mg or 22 mg.
  • the treatment comprises the administration of apigenin or an apigenin glycoside in an average daily dose of 0.2 mg or more as determined in accordance with the method described in the USP chamomile monograph, preferably 1 mg or more, preferably 3 mg or more and/or in an amount of 30 mg or less in accordance with the method described in the USP chamomile monograph, preferably 20 mg or less, preferably 8 mg or less.
  • the treatment comprises the administration of Matricaria chamomilla flower extract in an average daily dose of 10 mg or more, preferably 40 mg or more, preferably 60 mg or more and/or in an amount of 300 mg or less, preferably 150 mg or less, preferably 120 mg or less, such as 60 mg, 70 mg, 80 mg, 90 mg or 110 mg.
  • the treatment comprises the administration of vitamin D, preferably vitamin D3 in an amount of 0.02 mg or more, preferably 0.2 mg or more, preferably 2 mg or more and/or in an amount of 40 mg or less, preferably 20 mg or less, preferably 4 mg or less.
  • the treatment comprises the administration of vitamin D, preferably vitamin D3, in an amount of 0.2 pg or more, preferably 0.12 pg or more, preferably 2 pg or more and/or in an amount of 80 pg or less, preferably 30 pg or less, preferably 8 pg or less.
  • the treatment comprises the administration of a magnesium compound, preferably magnesium carbonate, preferably magnesium carbonate in the form of the dypingite mineral in an amount of 20 mg or more, preferably 200 mg or more, preferably 1100 mg or more and/or in an amount of 4000 mg or less, preferably 2000 mg or less, preferably 1300 mg or less.
  • a magnesium compound preferably magnesium carbonate, preferably magnesium carbonate in the form of the dypingite mineral in an amount of 20 mg or more, preferably 200 mg or more, preferably 1100 mg or more and/or in an amount of 4000 mg or less, preferably 2000 mg or less, preferably 1300 mg or less.
  • the treatment comprises the daily administration of:
  • Perilla frutescens seed extract in an amount of 60 mg or more and in an amount of 1 10 mg or less;
  • Vitex agnus-castus fruit extract in an amount of 20 mg or more and in an amount of 40 mg or less;
  • Crocus sativus stigma extract in an amount of 10 mg or more and in an amount of 30 mg or less;
  • Matricaria chamomilla flower extract in an amount of 60 mg or more and in an amount of 120 mg or less;
  • vitamin D preferably vitamin D3 in an amount of 2 mg or more and in an amount of 4 mg or less;
  • a magnesium compound preferably magnesium carbonate, preferably magnesium carbonate in the form of the dypingite mineral in an amount of 1100 mg or more and in an amount of 1300 mg or less;
  • fatty acid glycerides preferably a diester formed from glycerol and a C20- C24 saturated fatty acid, preferably glycerol dibehenate in an amount of 12 mg or more and in an amount of 20 mg or less.
  • the treatment comprises the daily administration of:
  • Perilla frutescens seed extract in an amount of 60 mg or more and in an amount of 1 10 mg or less;
  • Vitex agnus-castus fruit extract in an amount of 20 mg or more and in an amount of 40 mg or less;
  • Crocus sativus stigma extract in an amount of 10 mg or more and in an amount of 30 mg or less; • Matricaria chamomilla flower extract in an amount of 60 g or more and in an amount of 120 mg or less;
  • vitamin D preferably vitamin D3 in an amount of 2 pg or more and in an amount of 8 pg or less;
  • a magnesium compound preferably magnesium carbonate, preferably magnesium carbonate in the form of the dypingite mineral in an amount of 1100 mg or more and in an amount of 1300 mg or less;
  • fatty acid glycerides preferably a diester formed from glycerol and a C20- C24 saturated fatty acid, preferably glycerol dibehenate in an amount of 12 mg or more and in an amount of 20 mg or less.
  • the treatments entail the administration of the composition in the form of a‘unit dosage form’ as defined herein before.
  • Unit dosage forms of the composition are preferably administered at least once a week, preferably at least once every 3 days, at least once every other day or at least once daily, most preferably once daily.
  • the treatment comprises the daily administration of one, two, three or four unit dosage forms, preferably one, two or three unit dosage forms, more preferably one or two. If more than one unit dosage form is administered per day, they may be taken simultaneously or consecutively at the same moment or they may be taken at intervals during the day, the former being preferred over the latter.
  • the treatment as defined herein before is continued for a period of at least two weeks, preferably at least 3 weeks, at least 4 weeks, at least 1 month, at least two months, at least three months, at least 4 months, at least 5 months, or at least 6 months.
  • the treatment comprises the daily oral administration of one or two unit dosage forms, preferably the daily oral administration of two unit dosage forms, more preferably the daily oral administration of two unit dosage forms simultaneously or consecutively at the same moment, wherein the treatment is continued for a period of at least 3 months.
  • a compartment refers to one or more than one compartment.
  • composition in tablet form is prepared according to the ingredient list provided in Table 1.
  • a first blend comprising chasteberry fruit extract, vitamin D and magnesium citrate passed through a mesh screen is prepared by blending until uniformly mixed.
  • a second blend is prepared comprising Perilla frutescens leaf extract, saffron stigmates extract and calcium carbonate.
  • a third blend is made with chamomile and vitamin D. The ingredients used are selected to provide a per tablet amount as indicated in Table 1. All blends are passed through a mesh screen. The blends are combined and mixed long enough to ensure content uniformity as is commonly known and practiced in the art. The tableting mixture is discharged. Capsule shaped tablets with a target weight of 1410 mg (+/- 5%) are compressed with a target hardness of 8-12 kP.
  • Tablets prepared according to the composition provided in Table 1 may optionally be coated with a layer.
  • the tablets are coated (Aquapolish F pink) using a conventional pan coating process.
  • Table 1 pharmaceutical composition according to an embodiment of the invention
  • the trial objectives are:
  • subjects may have a sequential increase in dose at monthly intervals from 2 to 3 tablets a day to optimize response. Provisions are made for dose decreases in case of tolerability concerns.
  • the primary outcome measure is the mean change from the end of the placebo period in luteal phase total COPE score after three menstrual cycles of active treatment.
  • Secondary efficacy measures include; mean change from the end of the placebo period in luteal phase total COPE score; mean change from end of the placebo period in luteal phase physical COPE symptoms; mean change from the end of the luteal phase behavioral symptoms; mean change from end of the placebo period in follicular phase total COPE score; CGI improvement score at each of the three menstrual cycles.
  • a study to evaluate the efficacy of the formulation described in example 1 (‘study product’) in treating PMS is carried out. 50 female patients aged 15-40 years which are not using hormonal contraception are treated with the study product (840 mg tablets as described in example 1). The administration regimen was two tablets per day for three months, taken orally (simultaneously or consecutively) with a large glass of water before breakfast.
  • the efficacy of the study product is evaluated by self-assessment of the study participants at the start of treatment and after 3 months using the form shown as Table 2.
  • the participants use the form by allocating a severity score (light, moderate or severe) to each of the 18 criteria.
  • Table 2 self-assessment form
  • An overall assessment score is calculated as follows:
  • Women benefiting from the product continue the treatment for another 3 months and provide another self-assessment after a total of 6 months of treatment.
  • the study product is well-tolerated and efficacious in improving one or more of the symptoms in the evaluation form of Table 2 after 3 months of treatment. Furthermore, the study product decreases the overall assessment score after 3 months of treatment by more than 4 in a large portion of individuals compared to the overall assessment score at the start of treatment, when administered orally at a dosage of two tablets per day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne des compositions comprenant de la Vicénine-2 qui sont utiles dans le traitement de sujets féminins souffrant d'un syndrome prémenstruel et/ou d'une gêne menstruelle. Dans des modes de réalisation particuliers, l'invention concerne des compositions comprenant de la Vicénine-2 en association avec un ou plusieurs autres ingrédients tels que l'acide rosmarinique, les clérodadiénols, la crocine, le safranal, les apigénines, la vitamine D et le magnésium. En outre, l'invention concerne la prévention, la guérison et/ou le soulagement d'au moins un symptôme associé au syndrome prémenstruel et/ou à une gêne menstruelle à l'aide des compositions de l'invention.
PCT/EP2020/063054 2019-05-10 2020-05-11 Traitement du syndrome prémenstruel et/ou d'une gêne menstruelle par une composition comprenant de la vicénine -2 Ceased WO2020229412A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173890.5 2019-05-10
EP19173890 2019-05-10

Publications (1)

Publication Number Publication Date
WO2020229412A1 true WO2020229412A1 (fr) 2020-11-19

Family

ID=66483963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/063054 Ceased WO2020229412A1 (fr) 2019-05-10 2020-05-11 Traitement du syndrome prémenstruel et/ou d'une gêne menstruelle par une composition comprenant de la vicénine -2

Country Status (1)

Country Link
WO (1) WO2020229412A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024145374A1 (fr) * 2022-12-28 2024-07-04 Access Business Group International Llc Composition pour prévenir et/ou améliorer des symptômes et/ou des désagréments de cycle menstruel, et procédés de production et d'utilisation de celle-ci

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330240A1 (fr) 1988-02-26 1989-08-30 Robugen Gmbh Pharmazeutische Fabrik Médicament à base de camomille et son application à la préparation d'extraits de camomille, d'huile de camomille et de moyens pharmaceutiques
EP0496230A1 (fr) 1991-01-23 1992-07-29 ASTA Medica Aktiengesellschaft Préparation d'un extrait de camomille à qualité antimicrobienne
US20070237839A1 (en) * 2006-03-30 2007-10-11 Yangsen Biotechnology Co., Ltd. Compositions and methods for uterine relaxing
US20100297230A1 (en) * 2009-05-21 2010-11-25 Key Naturals Inc. Compositions and methods for prostate and menstrual/menopausal related health
EP2444061A1 (fr) 2009-06-17 2012-04-25 Kao Corporation Composition contenant de l'apigénine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330240A1 (fr) 1988-02-26 1989-08-30 Robugen Gmbh Pharmazeutische Fabrik Médicament à base de camomille et son application à la préparation d'extraits de camomille, d'huile de camomille et de moyens pharmaceutiques
EP0496230A1 (fr) 1991-01-23 1992-07-29 ASTA Medica Aktiengesellschaft Préparation d'un extrait de camomille à qualité antimicrobienne
US20070237839A1 (en) * 2006-03-30 2007-10-11 Yangsen Biotechnology Co., Ltd. Compositions and methods for uterine relaxing
US20100297230A1 (en) * 2009-05-21 2010-11-25 Key Naturals Inc. Compositions and methods for prostate and menstrual/menopausal related health
EP2444061A1 (fr) 2009-06-17 2012-04-25 Kao Corporation Composition contenant de l'apigénine

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Chamomile: Industrial Profiles", 2005
A.V LOSKUTOVC.W BENINGERG.L HOSFIELDK.C SINK: "Development of an improved procedure for extraction and quantitation of safranal in stigmas of Crocus sativus L. using high performance liquid chromatography", FOOD CHEMISTRY, vol. 69, no. 1, 2000, pages 87 - 95, XP009193692, DOI: 10.1016/S0308-8146(99)00246-0
ALAM, PRAVEJF ELKHOLY, SHEREENHOSOKAWA, MUNETAKAA MAHFOUZ, SABRYA SHARAF-ELDIN, MAHMOUD: "Simultaneous extraction and rapid HPLC based quantification of crocin and safranal in Saffron (Crocus sativus L.", INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 8, 2016, pages 224 - 227
ALONSO, G.L.SALINAS, M.R.GARIJO, J.SANCHEZ-FERNANDEZ, M.A.: "Composition of crocins and picrocrocin from Spanish saffron (Crocus sativus L.", J. FOOD QUAL., vol. 24, 2001, pages 219 - 233
ANONYMOUS: "Agnus castus STADA", July 2017 (2017-07-01), XP055639857, Retrieved from the Internet <URL:https://www.stada.de/media/produkte/dokumente/gebrauchsinformationen/AGNUS_CASTUS_4MG_FTA_SD_DE_GI_9216151_1705_web.pdf> [retrieved on 20191107] *
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 42553-65-1
CHEN M-LWU C-HHUNG L-SLIN B-F: "Ethanol Extract of Perilla frutescens Suppresses Allergen-Specific Th2 Responses and Alleviates Airway Inflammation and Hyperreactivity in Ovalbumin-Sensitized Murine Model of Asthma", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE: ECAM, vol. 2015, 2015, pages 324265
CHEN S-NFRIESEN JBWEBSTER D ET AL.: "Phytoconstituents from Vitex agnus-castus fruits", FITOTERAPIA, vol. 82, no. 4, 2011, pages 528 - 533
CHRISTIAN REICHARDT: "Solvents and Solvent Effects in Organic Chemistry", 2003, WILEY-VCH PUBLISHERS
ELEONORA URBANIFRANCESCA BLASICLAUDIA CHIESIANGELA MAURIZILINA COSSIGNANI: "Characterization of Volatile Fraction of Saffron from Central Italy (Cascia, Umbria", INTERNATIONAL JOURNAL OF FOOD PROPERTIES, vol. 18, no. 10, 2015, pages 2223 - 2230
EUGEN J. VERSPOHL ET AL: "Testing of Perilla frutescens extract and Vicenin 2 for their antispasmodic effect", PHYTOMEDICINE, vol. 20, no. 5, March 2013 (2013-03-01), AMSTERDAM, NL, pages 427 - 431, XP055639860, ISSN: 0944-7113, DOI: 10.1016/j.phymed.2012.12.018 *
HADIZADEH, F.S. A. MOHAJERIM. SEIFI: "Extraction and purification of crocin from saffron stigmas employing a simple and efficient crystallization method", PAKISTAN JOURNAL OF BIOLOGICAL SCIENCES, vol. 13.14, 2010, pages 691
HOBERG EORJALA JMEIER BSTICHER O, DITERPENOIDS FROM THE FRUITS OF VITEX AGNUS CASTUS
HOBERG ET AL., AM J PHYSIOL, 1989, pages R276 - 80
ISLAM, MD NURUL ET AL.: "Vicenin 2 isolated from Artemisia capillaris exhibited potent anti-glycation properties", FOOD AND CHEMICAL TOXICOLOGY, vol. 69, 2014, pages 55 - 62
JARRY H ET AL: "In vitro assays for bioactivity-guided isolation of endocrine active compounds in Vitex agnus-castus", MATURITAS, ELSEVIER, AMSTERDAM, NL, vol. 55, November 2006 (2006-11-01), pages S26 - S36, XP027972082, ISSN: 0378-5122, [retrieved on 20061101] *
JUN, HYUN-II ET AL.: "Structural characterization of phenolic antioxidants from purple perilla (Perilla frutescens var. acuta) leaves", FOOD CHEMISTRY, vol. 148, 2014, pages 367 - 372
KANAKIS, CHARALABOS D. ET AL.: "Qualitative determination of volatile compounds and quantitative evaluation of safranal and 4-hydroxy-2, 6, 6-trimethyl-1-cyclohexene-1-carboxaldehyde (HTCC) in Greek saffron", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 52.14, 2004, pages 4515 - 4521
LI, N.LIN, G.KWAN, Y.W.MIN, Z.D.: "Simultaneous quantification of five major biologically active ingredients of saffron by high-performance liquid chromatography", J. CHROMATOGR. A, vol. 849, 1999, pages 349 - 355, XP004174285, DOI: 10.1016/S0021-9673(99)00600-7
LOZANO, P. ET AL.: "A non-destructive method to determine the safranal content of saffron (Crocus sativus L.) by supercritical carbon dioxide extraction combined with high-performance liquid chromatography and gas chromatography", JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 43.1-3, 2000, pages 367 - 378
M. KOSARB. DEMIRCIF. GOGERI. KARAK.H.C. BASER: "Volatile composition, antioxidant activity, and antioxidant components in saffron cultivated in Turkey", INTERNATIONAL JOURNAL OF FOOD PROPERTIES, vol. 20, no. 1, 2017, pages S746 - S754
MARRASSINI, CARLA ET AL.: "Vicenin-2, a potential anti-inflammatory constituent of Urtica circularis", JOURNAL OF NATURAL PRODUCTS, vol. 74.6, 2011, pages 1503 - 1507, XP002671451, DOI: 10.1021/NP100937E
RAPKIN A., A REVIEW OF TREATMENT OF PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER PSYCHONEUROENDOCRINOLOGY, vol. 28, no. 3, August 2003 (2003-08-01), pages 39 - 53
REMINGTON: "The Science and Practice of Pharmacy", 2012, article "Oral solid dosage forms"
SRIVASTAVA JKGUPTA S. EXTRACTION: "Characterization, Stability and Biological Activity of Flavonoids Isolated from Chamomile Flowers", MOLECULAR AND CELLULAR PHARMACOLOGY, vol. 1, no. 3, 2009, pages 138, XP055135028, DOI: 10.4255/mcpharmacol.09.18
TARANTILIS, PETROS A.MOSCHOS POLISSIOUMICHEL MANFAIT: "Separation of picrocrocin, cis-trans-crocins and safranal of saffron using high-performance liquid chromatography with photodiode-array detection", JOURNAL OF CHROMATOGRAPHY A, vol. 664.1, 1994, pages 55 - 61, XP026531595, DOI: 10.1016/0021-9673(94)80628-4
WHELAN A M ET AL: "Herbs, vitamins and minerals in the treatment of premenstrual syndrome: A systematic review", CANADIAN JOURNAL OF CLINICAL PHARMACOLOGY - JOURNAL CANADIEN DEPHARMACOLOGIE CLINIQUE, CANADIAN SOCIETY OF PHARMACOLOGY AND THERAPEUTICS, OAKVILLE, CANADA, vol. 16, no. 3, 2009, pages e407 - e429, XP009145713, ISSN: 1198-581X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024145374A1 (fr) * 2022-12-28 2024-07-04 Access Business Group International Llc Composition pour prévenir et/ou améliorer des symptômes et/ou des désagréments de cycle menstruel, et procédés de production et d'utilisation de celle-ci

Similar Documents

Publication Publication Date Title
US10842805B2 (en) Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
CA2803360C (fr) Composition destinee a ameliorer le bien-etre sexuel
US8173181B2 (en) Method and composition for improved anabolism
US10849950B2 (en) Composition for treating fatty liver
CN105380051A (zh) 一种解酒护肝饮料及其制备方法
Shin et al. Current status and clinical studies of oriental herbs in sexual medicine in Korea
Lanje et al. Medicinal natural drug of Valerian (Valerina Officinalis): an-over review
US20110189319A1 (en) Lifeforce liquid supplement
Boon et al. The complete natural medicine guide to the 50 most common medicinal herbs
US11426439B2 (en) Nutritional product and method of using it
KR101456937B1 (ko) 천연물 추출물로 구성된 비만의 억제 및 치료용 조성물
KR20150087968A (ko) 노화 및 관절염의 예방 또는 치료용 조성물
WO2020229412A1 (fr) Traitement du syndrome prémenstruel et/ou d&#39;une gêne menstruelle par une composition comprenant de la vicénine -2
Bartels et al. Herbal and related remedies
WO2021064132A1 (fr) Traitement du syndrome de la ménopause et/ou des symptômes associés à la ménopause
Consolini et al. Patterns of self-medication with medicinal plants and related adverse events-a South American survey
EP3111930B1 (fr) Composition pour le traitement de dépressions, de troubles bipolaires, de troubles dépressifs récidivants et d&#39;autres troubles affectifs persistants
ES2859524T3 (es) Composición para el uso en el tratamiento de la disforia, la depresión y/o los cambios de ánimo relacionados con el síndrome premenstrual (SPM)
CN118303621B (zh) 用于改善女性更年期症状的组合物及制备方法
AU2015266075B2 (en) Oral composition for improving systemic symptoms including sensitivity to cold
WO2022259195A1 (fr) Composition orale pour le traitement et/ou la prévention de troubles associés à la ménopause
Aswar et al. Molecular Mechanism of Action of Phytoconstituents in Neuropsychiatric Disorders
Wang et al. TCM Substances in Neuropsychopharmacotherapy
CN112168893B (zh) 一种中药组合物用于改善围绝经期妇女综合征症的用途
CN112168892B (zh) 一种用于改善围绝经期妇女综合征症的中药组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20723441

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20723441

Country of ref document: EP

Kind code of ref document: A1